Resistance to antiplatelet drugs: Current status and future research

Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Platelet reactivity and activation are important factors during the development of atherothrombotic processes and subsequent ischaemic complications. Pharmacological agents that suppress platelet function are proved to be the most efficient in the prevention and treatment of thrombotic complications. As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. The main antiplatelet drugs are aspirin (which inhibits thromboxane synthesis), thienopyridines (which block P2Y12 receptors) and glycoprotein IIb/IIIa antagonists (which block glycoprotein IIb/IIIa receptors). In recent years, resistance or nonresponsiveness to antiplatelet therapy has been reported and, more importantly, are linked to the occurrence of adverse cardiovascular events. New treatment strategies to overcome nonresponsiveness are being sought. A focus on the development of simple, reproducible and user friendly point-of-care methods to determine aspirin/clopidogrel responsiveness should be undertaken to assist clinicians in tailoring antiplatelet therapy to the individual patient.

Original languageEnglish (US)
Pages (from-to)2027-2045
Number of pages19
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number12
DOIs
StatePublished - Oct 2005

Fingerprint

Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
clopidogrel
Platelet Activation
Aspirin
Thienopyridines
Point-of-Care Systems
Thromboxanes
Therapeutics
Thrombosis
Blood Platelets
Pharmacology

Keywords

  • Aspirin
  • Clopidogrel
  • Platelet
  • Resistance
  • Response variability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Resistance to antiplatelet drugs : Current status and future research. / Tantry, Udaya S.; Bliden, Kevin P.; Gurbel, Paul A.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 12, 10.2005, p. 2027-2045.

Research output: Contribution to journalArticle

Tantry, Udaya S. ; Bliden, Kevin P. ; Gurbel, Paul A. / Resistance to antiplatelet drugs : Current status and future research. In: Expert Opinion on Pharmacotherapy. 2005 ; Vol. 6, No. 12. pp. 2027-2045.
@article{5dc9020868224a939d9ee9e41770610c,
title = "Resistance to antiplatelet drugs: Current status and future research",
abstract = "Platelet reactivity and activation are important factors during the development of atherothrombotic processes and subsequent ischaemic complications. Pharmacological agents that suppress platelet function are proved to be the most efficient in the prevention and treatment of thrombotic complications. As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. The main antiplatelet drugs are aspirin (which inhibits thromboxane synthesis), thienopyridines (which block P2Y12 receptors) and glycoprotein IIb/IIIa antagonists (which block glycoprotein IIb/IIIa receptors). In recent years, resistance or nonresponsiveness to antiplatelet therapy has been reported and, more importantly, are linked to the occurrence of adverse cardiovascular events. New treatment strategies to overcome nonresponsiveness are being sought. A focus on the development of simple, reproducible and user friendly point-of-care methods to determine aspirin/clopidogrel responsiveness should be undertaken to assist clinicians in tailoring antiplatelet therapy to the individual patient.",
keywords = "Aspirin, Clopidogrel, Platelet, Resistance, Response variability",
author = "Tantry, {Udaya S.} and Bliden, {Kevin P.} and Gurbel, {Paul A.}",
year = "2005",
month = "10",
doi = "10.1517/14656566.6.12.2027",
language = "English (US)",
volume = "6",
pages = "2027--2045",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Resistance to antiplatelet drugs

T2 - Current status and future research

AU - Tantry, Udaya S.

AU - Bliden, Kevin P.

AU - Gurbel, Paul A.

PY - 2005/10

Y1 - 2005/10

N2 - Platelet reactivity and activation are important factors during the development of atherothrombotic processes and subsequent ischaemic complications. Pharmacological agents that suppress platelet function are proved to be the most efficient in the prevention and treatment of thrombotic complications. As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. The main antiplatelet drugs are aspirin (which inhibits thromboxane synthesis), thienopyridines (which block P2Y12 receptors) and glycoprotein IIb/IIIa antagonists (which block glycoprotein IIb/IIIa receptors). In recent years, resistance or nonresponsiveness to antiplatelet therapy has been reported and, more importantly, are linked to the occurrence of adverse cardiovascular events. New treatment strategies to overcome nonresponsiveness are being sought. A focus on the development of simple, reproducible and user friendly point-of-care methods to determine aspirin/clopidogrel responsiveness should be undertaken to assist clinicians in tailoring antiplatelet therapy to the individual patient.

AB - Platelet reactivity and activation are important factors during the development of atherothrombotic processes and subsequent ischaemic complications. Pharmacological agents that suppress platelet function are proved to be the most efficient in the prevention and treatment of thrombotic complications. As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. The main antiplatelet drugs are aspirin (which inhibits thromboxane synthesis), thienopyridines (which block P2Y12 receptors) and glycoprotein IIb/IIIa antagonists (which block glycoprotein IIb/IIIa receptors). In recent years, resistance or nonresponsiveness to antiplatelet therapy has been reported and, more importantly, are linked to the occurrence of adverse cardiovascular events. New treatment strategies to overcome nonresponsiveness are being sought. A focus on the development of simple, reproducible and user friendly point-of-care methods to determine aspirin/clopidogrel responsiveness should be undertaken to assist clinicians in tailoring antiplatelet therapy to the individual patient.

KW - Aspirin

KW - Clopidogrel

KW - Platelet

KW - Resistance

KW - Response variability

UR - http://www.scopus.com/inward/record.url?scp=27744444421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744444421&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.12.2027

DO - 10.1517/14656566.6.12.2027

M3 - Article

C2 - 16197357

AN - SCOPUS:27744444421

VL - 6

SP - 2027

EP - 2045

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -